Perspectives on lantibiotic discovery-where have we failed and what improvements are required?

Expert Opinion on Drug Discovery

Volumn 10, Issue 4, 2015, Pages 315-320

  Sandiford, Stephanie Kate ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti microbial; Biosynthesis; Genome mining; Heterologous expression; Infectious disease; Microbial resistance

Indexed keywords

LANCOVUTIDE; LANTIBIOTIC; MICROBISPORICIN; MUTACIN 1140; NVB 302; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIOCIN;

ANTIMICROBIAL ACTIVITY; CLOSTRIDIUM DIFFICILE INFECTION; CYSTIC FIBROSIS; DRUG EFFICACY; GENE SEQUENCE; GENOME ANALYSIS; GRAM POSITIVE BACTERIUM; HUMAN; MULTIDRUG RESISTANCE; MUTAGENESIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; BACTERIUM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIOCINS; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84925297771     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1016496     Document Type: Review

References (56)

1. European centre for disease prevention and control/European medicine agency joint technical report. The bacterial challenge: Time to react. Press Release 2009. doi 10.2900/2518
2. Oman TJ, van der Donk WA. Follow the leader: the use of leader peptides to guide natural product biosynthesis. Nat Chem Biol 2010; 6(1): 9-18
3. Allgaier H, Jung G, Werner RG, et al. Epidermin: sequencing of a heterodet tetracyclic 21-peptide amide antibiotic. Eur J Biochem 1986; 160: 9-22
4. Schnell N, Entian KD, Schneider U, et al. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature 1988; 333(6170): 276-8
5. Gotz F, Perconti S, Popella P, et al. Epidermin and gallidermin: staphylococcal lantibiotics. Int J Med Microbiol 2014; 304(1): 63-71
6. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Disc 2007; 6(1): 29-40
7. Dischinger J, Chipalu SB, Bierbaum G. Lantibiotics: promising candidates for future applications in health care. Int J Med Microbiol 2014; 304(1): 51-62
8. Pag U, Sahl HG. Multiple activities in lantibiotics-models for the design of novel antibiotics? Curr Pharm Des 2002; 8(9): 815-33
9. Brotz H, Josten M, Wiedemann I, et al. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 1998; 30(2): 317-27
10. Hasper HE, Kramer NE, Smith JL, et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid ii. Science 2006; 313(5793): 1636-7
11. Boakes S, Wadman S. The therapeutic potential of lantibiotics. Drug Dis Devel 2008; 27: 22-5
12. Nascimento JS, Ceotto H, Nascimento SB, et al. Bacteriocins as alternative agents for control of multiresistant staphylococcal strains. Lett Appl Microbiol 2006; 42: 215-21
13. Fontana MB, Bastos MC, Brandelli A. Bacteriocins pep5 and epidermin inhibit staphylococcus epidermidis adhesion to catheters. Curr Microbiol 2006; 52: 350-3
14. Kruszewska D, Sahl HG, Bierbaum G, et al. Mersacidin eradicates methicillinresistant staphylococcus aureus (mrsa) in a mouse rhinitis model. J Antimicrob Chemother 2004; 54(3): 648-53
15. Lubelski J, Rink R, Khusainov R, et al. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol Life Sci 2008; 65(3): 455-76
16. Mattick AT, Hirsch A, Berridge NJ. Further observations on an inhibitory substance (nisin) from lactic streptococci. Lancet 1947; 250(6462): 5-8
17. Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic mu1140. J Pharm Sci 2010; 99(5): 2521-8
18. Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic mu1140. Int J Antimicrob Agents 2009; 33(1): 70-4
19. Jabes D, Brunati C, Candiani G, et al. Efficacy of the new lantibiotic nai-107 in experimental infections induced by multidrug-resistant gram-positive pathogens. Antimicrob Agents Chemother 2011; 55(4): 1671-6
20. Crowther GS, Baines SD, Todhunter SL, et al. Evaluation of nvb302 versus vancomycin activity in an in vitro human gut model of clostridium difficile infection. J Antimicrob Chemother 2013; 68(1): 168-76
21. Jones A, Helm J. Emerging treatments in cystic fibrosis. Drugs 2009; 69(14): 1903-10
22. Tagg J, Dajani A, Wannamaker L. Bacteriocins of gram-positive bacteria. Bacteriol Rev 1976; 40(3): 722-56
23. Tagg JR, Bannister LV. "Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J Med Microbiol 1979; 12(4): 397-411
24. Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev 1995; 59: 171-200
25. Zhu H, Sandiford S, Wezel G. Triggers and cues that activate antibiotic production by actinomycetes. J Ind Microbiol Biotechnol 2014; 41(2): 371-86
26. Kies S, Vuong C, Hille M, et al. Control of antimicrobial peptide synthesis by the agr quorum sensing system in staphylococcus epidermidis: activity of the lantibiotic epidermin is regulated at the level of precursor peptide processing. Peptides 2003; 24: 329-38
27. Kuipers OP, Beerthuyzen MM, de Ruyter PG, et al. Autoregulation of nisin biosynthesis in lactococcus lactis by signal transduction. J Biol Chem 1995; 270(45): 27299-304
28. Schmitz S, Hoffmann A, Szekat C, et al. The lantibiotic mersacidin is an autoinducing peptide. Appl Environ Microbiol 2006; 72(11): 7270-7
29. Perez R, Zendo T, Sonomoto K. Novel bacteriocins from lactic acid bacteria (lab): various structures and applications. Microb Cell Fact 2014; 13(Suppl 1): S3
30. Zendo T, Nakayama J, Fujita K, et al. Bacteriocin detection by liquid chromatography/mass spectrometry for rapid identification. J Appl Microbiol 2008; 104(2): 499-507
31. Li J, Girard G, Florea BI, et al. Identification and isolation of lantibiotics from culture: a bioorthogonal chemistry approach. Org Biomol Chem 2012; 10(43): 8677-83
32. Smith L, Novák J, Rocca J, et al. Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. Eur J Biochem 2000; 267(23): 6810-16
33. Begley M, Cotter PD, Hill C, et al. Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for lanM proteins. Appl Environ Microbiol 2009; 75(17): 5451-60
34. van Heel AJ, de Jong A, Montalbán-López M, et al. Bagel3: Automated identification of genes encoding bacteriocins and (non-) bactericidal posttranslationally modified peptides. Nucleic Acids Res 2013; 41(W1): W448-53
35. Blin K, Medema MH, Kazempour D, et al. Antismash 2.0-A versatile platform for genome mining of secondary metabolite producers. Nucleic Acids Res 2013; 41(W1): W204-12
36. Hammami R, Zouhir A, Le Lay C, et al. Bactibase second release: a database and tool platform for bacteriocin characterization. BMC Microbiol 2010; 10(1): 22
37. De La Fuente R, Sonawane ND, Arumainayagam D, et al. Small molecules with antimicrobial activity against e. Coli and p. Aeruginosa identified by high-Throughput screening. Br J Pharmacol 2006; 149(5): 551-9
38. Ymele-Leki P, Cao S, Sharp J, et al. A high-Throughput screen identifies a new natural product with broadspectrum antibacterial activity. PLoS One 2012; 7(2): e31307
39. Castiglione F, Lazzarini A, Carrano L, et al. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 2008; 15(1): 22-31
40. Castiglione F, Cavaletti L, Losi D, et al. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete planomonospora sp. Biochemistry 2007; 46(20): 5884-95
41. Rollema HS, Kuipers OP, Both P, et al. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995; 61(8): 2873-8
42. Field D, Begley M, O'Connor PM, et al. Bioengineered nisin a derivatives with enhanced activity against both gram positive and gram negative pathogens. PLoS One 2012; 7(10): e46884
43. Mothia B, Appleyard AN, Wadman S, et al. Synthesis of peptides containing overlapping lanthionine bridges on the solid phase: an analogue of rings d and e of the lantibiotic nisin. Org Lett 2011; 13(16): 4216-19
44. Liu W, Chan AS, Liu H, et al. Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147. J Am Chem Soc 2011; 133(36): 14216-19
45. Yuan J, Zhang ZZ, Chen XZ, et al. Site directed mutagenesis of the hinge region of nisin z and properties of nisin z mutants. Appl Microbiol Biotechnol 2004; 64: 806-15
46. Appleyard AN, Choi S, Read DM, et al. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol 2009; 16(5): 490-8
47. Bonelli RR, Schneider T, Sahl HG, et al. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode of action studies. Antimicrob Agents Chemother 2006; 50: 1449-57
48. van Heel AJ, Mu D, Montalbán-López M, et al. Designing and producing modified, new-To-nature peptides with antimicrobial activity by use of a combination of various lantibiotic modification enzymes. ACS Synthetic Biology 2013; 2(7): 397-404
49. Arnusch CJ, Bonvin AM, Verel AM, et al. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant enterococci. Biochemistry 2008; 47(48): 12661-3
50. Whitehead HR. A substance inhibiting bacterial growth, produced by certain strains of lactic streptococci. Biochem J 1933; 27(6): 1793-800
51. Jansen EF, Hirschmann DJ. Subtilin. An antibacterial product of bacillus subtilis. Culturing conditions and properties. Arch Biochem Biophys 1944; 4: 297-309
52. Fuchs SW, Jaskolla T, Bochmann S, et al. Entianin, a novel subtilin-like lantibiotic from bacillus subtilis subsp. Spizizenii dsm 15029t with high antimicrobial activity. Appl Environ Microbiol 2011; 77(5): 1698-707
53. Hillman JD, Novák J, Sagura E, et al. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from streptococcus mutans. Infect Immun 1998; 66(6): 2743-9
54. Georgalaki MD, Van den Berghe E, Kritikos D, et al. Macedocin, a food-grade lantibiotic produced by streptococcus macedonicus aca-dc 198. Appl Environ Microbiol 2002; 68(12): 5891-903
55. Ross KF, Ronson CW, Tagg JR. Isolation and characterization of the lantibiotic salivaricin a and its structural gene sala from streptococcus salivarius 20p3. Appl Environ Microbiol 1993; 59(7): 2014-21
56. Lawton EM, Cotter PD, Hill C, et al. Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile bacillus halodurans c-125. FEMS Microbiol Lett 2007; 267(1): 64-71